MIM
BEAM icon

MetLife Investment Management’s Beam Therapeutics BEAM Stock Holding History

MetLife Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Sell
52,994
-1,529
-3% -$42.4K 0.01% 1291
2025
Q4 		$1.51M Sell
54,523
-2,053
-4% -$52.4K 0.01% 1216
2025
Q3 		$1.37M Hold
56,576
– – 0.01% 1279
2025
Q2 		$962K Buy
56,576
+1,568
+3% +$27.3K 0.01% 1338
2025
Q1 		$1.07M Buy
55,008
+8,108
+17% +$212K 0.01% 1333
2024
Q4 		$1.16M Buy
46,900
+3,366
+8% +$85.9K 0.01% 1334
2024
Q3 		$1.07M Hold
43,534
– – 0.01% 1356
2024
Q2 		$1.02M Buy
43,534
+5,450
+14% +$134K 0.01% 1341
2024
Q1 		$1.26M Hold
38,084
– – 0.01% 1173
2023
Q4 		$1.04M Buy
38,084
+2,054
+6% +$51K 0.01% 1270
2023
Q3 		$867K Hold
36,030
– – 0.01% 1307
2023
Q2 		$1.15M Buy
36,030
+2,640
+8% +$85.7K 0.01% 1192
2023
Q1 		$1.02M Hold
33,390
– – 0.01% 1215
2022
Q4 		$1.31M Sell
33,390
-989
-3% -$44.3K 0.01% 1081
2022
Q3 		$1.64M Buy
34,379
+1,325
+4% +$75.6K 0.01% 965
2022
Q2 		$1.28M Buy
33,054
+5,925
+22% +$236K 0.01% 1090
2022
Q1 		$1.55M Buy
27,129
+9,829
+57% +$645K 0.01% 1099
2021
Q4 		$1.38M Hold
17,300
– – 0.01% 997
2021
Q3 		$1.51M Buy
17,300
+497
+3% +$49.9K 0.01% 960
2021
Q2 		$2.16M Buy
16,803
+1,431
+9% +$114K 0.02% 842
2021
Q1 		$1.23M Hold
15,372
– – 0.01% 1056
2020
Q4 		$1.25M Hold
15,372
– – 0.01% 1029
2020
Q3 		$378K Buy
15,372
+8,751
+132% +$217K ﹤0.01% 1516
2020
Q2 		$185K Hold
6,621
– – ﹤0.01% 1956
2020
Q1 		$119K Buy
+6,621
New +$144K ﹤0.01% 1982

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

MetLife Investment Management's BEAM Position: Q1 2026 in Review

MetLife Investment Management reduced its Beam Therapeutics (BEAM) stake by 2.8% in Q1 2026, selling an estimated $42.4K and leaving 52,994 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #1291.

MetLife Investment Management first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $2.16M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • MetLife Investment Management held 52,994 shares of Beam Therapeutics worth $1.26M as of Q1 2026.
  • MetLife Investment Management sold 1,529 Beam Therapeutics shares in Q1 2026, an estimated $42.4K.
  • Beam Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1291 holding.
  • MetLife Investment Management first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • MetLife Investment Management's Beam Therapeutics position peaked at $2.16M in Q2 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.